European Headache Federation

The European Headache Federation is EU based scientific organization for headache. Official journal: The Journal of Headache and Pain

[European Headache Federation @EHF_Official]

A new study analyzed treatments for medication-overuse headache. The most effective approaches combined migraine prevention treatments with nerve blocks or anti-CGRP therapies. In contrast, stopping medication wasn’t very effective. https://t.co/iKPI80fIL7

[European Headache Federation @EHF_Official]

A novel optogenetic model of cortical spreading depression has been developed in awake, freely moving mice. Induction of CSD resulted in allodynia, photophobia, and anxiety-like behaviors, persisting up to 48 hours and alleviated by sumatriptan Read here: https://t.co/tLoKvqUqRH

[European Headache Federation @EHF_Official]

Preparations for the #EHC2025 are already in progress. But let's take this opportunity to look back on the outstanding congress at the end of 2024! Why don't you take a look at the video?
Will we see you again this year in Lisbon?
🔗 https://t.co/Bn49kz63Pb

[European Headache Federation @EHF_Official]

A new study across 8 Arab countries reveals high rates of undiagnosed migraine, with 31.7% of participants screening positive. Migraine causes significant disability, especially among housewives and those with comorbid conditions. Read the article here: https://t.co/1FFQII6o8k

[European Headache Federation @EHF_Official]

This narrative review summarizes recent data on the role of TRPM3 channels in migraine pathophysiology, particularly in women, the interplay between TRPM3 and CGRP signaling and the possible targeted therapies to be developed. https://t.co/zXzInoNy8j

[European Headache Federation @EHF_Official]

This comprehensive review summarizes the existing research on the connection between migraines and strokes! https://t.co/dk7OXAF7kD

[European Headache Federation @EHF_Official]

Join the @EFIC_org's congress, Pain in Europe XIV, under the theme “Comorbidity of #chronicpain & #mentalhealthdisorders: Breaking the cycle.” Experience a multidisciplinary program, connect with peers & explore innovative approaches to #painmanagement
🔗https://t.co/e3XlD7BfrT

[European Headache Federation @EHF_Official]

The effect of calcitonin gene-related peptide monoclonal antibodies on restless legs syndrome in patients with migraine, new findings from a retrospective study.

https://t.co/Pk1kJD7z6Y

[European Headache Federation @EHF_Official]

EUROPEAN HEADACHE FEDERATION - SCHOOL OF ADVANCED STUDIES (SAS)

ATHENS/GREECE, May 1/2 2025

Registration is open until March 23.

For additional information visit the event homepage: https://t.co/ctZgYPgKTf

[European Headache Federation @EHF_Official]

🌟🧠 Could substance P be the next breakthrough in migraine treatment? A new proposal explores its effects through clinical trials, paving the way for new therapies beyond CGRP & PACAP. 🔗 Read more: https://t.co/nY6mHIA4Zj #Migraine #Neuroscience #SubstanceP

[European Headache Federation @EHF_Official]

🧠🔬 αCGRP vs. βCGRP—do they localize differently in migraine pathways? A new study reveals that αCGRP, not βCGRP, is the key isoform in mouse trigeminal ganglion axons, with bioinformatics suggesting distinct intracellular sorting.
🔗 Read more: https://t.co/ezmKLZ44pJ #Migraine

[European Headache Federation @EHF_Official]

Why are migraine brains more prone to cortical spreading depression? This latest review explores genetic models of migraine, revealing how disease-linked mutations heighten CSD susceptibility shedding light on migraine aura: https://t.co/Y4IRHdmGho #Migraine #Neuroscience

[European Headache Federation @EHF_Official]

Does CGRP monoclonal antibody treatment affect blood pressure in patients with migraine?
Learn about the findings of a systematic review with potential clinical implications: https://t.co/7buRXYsDTx

[European Headache Federation @EHF_Official]

Could the use of PPIs be linked to headaches, especially migraines, by considering a person's genetics, environment, and other factors? Findings from a new review. https://t.co/mKsfI3zSDQ

[European Headache Federation @EHF_Official]

Multi-center study provides new and encouraging real-world efficacy and safety data for rimegepant. https://t.co/Y4vzSdL0c6

[European Headache Federation @EHF_Official]

Consistency between headache diagnoses and ICHD-3 criteria across different levels of care.

Agreement for the primary/secondary care and ICHD-3 was 77% for #migraine, 82% for TTH, and 96% for CH. Tertiary level diagnoses aligned with ICHD-3 in over 90%.

https://t.co/Z1g50S3Ry0

[European Headache Federation @EHF_Official]

Aura phenomenon: a proposal for an etiology-based clinical classification

This classification aims to aid in the diagnostic evaluation and phenotyping of aura phenomenon, ultimately improving the diagnosis and management.

https://t.co/st5LMXyCvG

#migraine #headache #neurology

[European Headache Federation @EHF_Official]

Part 2 of the review of the junior editorial board members’ vision explores the transformative potential of AI in addressing the complexities of headache disorders through innovative approaches. Read the review here: https://t.co/RKprxHPaz4

[European Headache Federation @EHF_Official]

A new review delves into the epidemiology, clinical presentation, and particular challenges of migraine in men. It discusses sex-specific triggers, hormonal influences, and comorbid conditions affecting migraine prevalence and severity in men, read here: https://t.co/85yOKPd2cS